1. Search Result
Search Result
Results for "

IDH1 Inhibitor 7-d<sub>2</sub>

" in MedChemExpress (MCE) Product Catalog:

2654

Inhibitors & Agonists

10

Biochemical Assay Reagents

13

Peptides

1

Inhibitory Antibodies

14

Natural
Products

13

Recombinant Proteins

2526

Isotope-Labeled Compounds

7

Antibodies

13

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-150238S

    Isocitrate Dehydrogenase (IDH) Cancer
    IDH1 Inhibitor 7-d2 is the deuterium labeled IDH1 Inhibitor 7 (HY-150238). IDH1 Inhibitor 7 is an IDH1 inhibitor with an IC50 of less than 100 nM [1] [2].
    <em>IDH1</em> Inhibitor <em>7-d</em><em>2</em>
  • HY-13972
    Mutant IDH1 inhibitor
    2 Publications Verification

    Isocitrate Dehydrogenase (IDH) Cancer
    Mutant IDH1 inhibitor is a potent mutant IDH1 R132H inhibitor with IC50 of < 72 nM.
    Mutant <em>IDH1</em> inhibitor
  • HY-41648

    Isocitrate Dehydrogenase (IDH) Cancer
    IDH1 Inhibitor 8 (91) is isocitrate dehydrogenase 1 (IDH1) inhibitor. IDH1 Inhibitor 8 can be used for the research of cancer [1].
    <em>IDH1</em> Inhibitor 8
  • HY-112601

    Isocitrate Dehydrogenase (IDH) Cancer
    IDH1 Inhibitor 1 is a potent, orally bioavailable, brain-penetrant and selective mutant IDH1 inhibitor with IC50s of 0.021 μM, 0.045 μM, and 2.52 μM for IDH1 R132H, IDH1 R132C, and IDH1 WT, respectively [1]. Anticancer activity [1].
    <em>IDH1</em> Inhibitor <em>1</em>
  • HY-143306

    Isocitrate Dehydrogenase (IDH) Cancer
    IDH1 Inhibitor 5 (compound 2) is an IDH1 (isocitrate dehydrogenase 1) inhibitor. IDH1 Inhibitor 5 inhibits MOG cells and wild-type IDH1 glioma cells with expressing exogenous mutant IDH1 R132H protein with IC50s of 64.4 and 34.9 nM, respectively [1].
    <em>IDH1</em> Inhibitor 5
  • HY-107977

    Isocitrate Dehydrogenase (IDH) Cancer
    IDH1 Inhibitor 3 (compound 6f) is a mutant isocitric dehydrogenase 1 (IDH1) inhibitor, with an IC50 of 45 nM for IDH1 R132H [1].
    <em>IDH1</em> Inhibitor 3
  • HY-150238

    Isocitrate Dehydrogenase (IDH) Cancer
    IDH1 Inhibitor 7 (Compound 88) is an IDH1 inhibitor with an IC50 of less than 100 nM [1].
    <em>IDH1</em> Inhibitor <em>7</em>
  • HY-128661

    Isocitrate Dehydrogenase (IDH) Metabolic Disease
    IDH1 Inhibitor 2 (compound 13) is a potent wild-type IDH1 inhibitor via a direct covalent modification of His315, with an IC50 of 110 nM [1].
    <em>IDH1</em> Inhibitor <em>2</em>
  • HY-RS06527

    Small Interfering RNA (siRNA) Others

    IDH1 Human Pre-designed siRNA Set A contains three designed siRNAs for IDH1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    IDH1 Human Pre-designed siRNA Set A
    IDH1 Human Pre-designed siRNA Set A
  • HY-RS06528

    Small Interfering RNA (siRNA) Others

    Idh1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Idh1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Idh1 Mouse Pre-designed siRNA Set A
    Idh1 Mouse Pre-designed siRNA Set A
  • HY-RS06529

    Small Interfering RNA (siRNA) Others

    Idh1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Idh1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Idh1 Rat Pre-designed siRNA Set A
    Idh1 Rat Pre-designed siRNA Set A
  • HY-149359

    Isocitrate Dehydrogenase (IDH) Cancer
    IHMT-IDH1-053 (compound 16) is a highly selectivity and irreversible IDH1-mutant inhibitor with an IC50 of 4.7 nM for IDH1 R132H. IHMT-IDH1-053 displays high selectivity against IDH1 mutants over IDH1 wt and IDH2 wt/mutants. IHMT-IDH1-053 inhibits 2-hydroxyglutarate (2-HG) production in IDH1 R132H mutant transfected 293T cells (IC50=28 nM). IHMT-IDH1-053 binds to the IDH1 R132H protein in the allosteric pocket adjacent to the NAPDH binding pocket through a covalent bond with residue Cys269. IHMT-IDH1-053 inhibits the proliferation of HT1080 cell line and primary AML cells which both bear IDH1 R132 mutants [1].
    IHMT-<em>IDH1</em>-053
  • HY-131312

    Mutant IDH1-IN-6

    Isocitrate Dehydrogenase (IDH) Cancer
    Mutant IDH1-IN-6 is a potent, selective and orally active mutant isocitrate dehydrogenase (IDH) inhibitor with IC50s of 6.27 nM, 3.71 nM, 36.9 nM and 11.5 nM for IDH1 R132H, IDH1 R132C, IDH2 R140Q and IDH2 R172K mutant enzymes, respectively. Mutant IDH1-IN-6 is less active at inhibiting the IDH wild-type enzymes [1].
    LY3410738
  • HY-12475
    Mutant IDH1-IN-1
    2 Publications Verification

    Isocitrate Dehydrogenase (IDH) Cancer
    Mutant IDH1-IN-1 is a mutant-selective IDH1 inhibitor with with IC50s of 4, 42, 80 and 143 nM against mutant IDH1 R132C/R132C, IDH1 R132H/R132H, IDH1 R132H/WT and wild type IDH1, respectively.
    Mutant <em>IDH1</em>-IN-<em>1</em>
  • HY-114459

    Isocitrate Dehydrogenase (IDH) Cancer
    Mutant IDH1-IN-4 (compound 434) is an inhibitor of mutant Isocitrate dehydrogenase 1 (IDH 1), with IC50 values of ≤ 0.5 μM for mutant IDH1 in R132H, HT1080 and U87R132H cells [1].
    Mutant <em>IDH1</em>-IN-4
  • HY-18717
    Mutant IDH1-IN-2
    2 Publications Verification

    Isocitrate Dehydrogenase (IDH) Cancer
    Mutant IDH1-IN-2 is a inhibitor of mutant Isocitrate dehydrogenase (IDH) proteins, with IC50 of in LS-MS biochemical assay, IC50 of 16.6 nM in Fluorescence biochemical assay.
    Mutant <em>IDH1</em>-IN-<em>2</em>
  • HY-145594

    AB-291; DS-1001

    Isocitrate Dehydrogenase (IDH) Cancer
    Safusidenib (AB-291; DS-1001) is an orally bioavailable, selective mutant IDH1 inhibitor. Safusidenib strongly inhibits mutant IDH1 but not wild-type IDH1. Safusidenib impairs tumor activity in chondrosarcoma [1]. Safusidenib exhibits activity against IDH1R132H, and IDH1R132C with IC50s of 15, and 130 nM in assays without any preincubation, respectively [2].
    Safusidenib
  • HY-110144

    Isocitrate Dehydrogenase (IDH) Cancer
    TC-E 5008 is a potent mutant IDH1 inhibitor with Ki values of 190 nM and 120 nM for R132H and R132C IDH1 mutants, respectively. TC-E 5008 exhibits very weak activity against WT-IDH1 with a Ki value of 12.3 μM. TC-E 5008 has anti-proliferative activity on multiple ER positive breast cancer cell lines [1] [2].
    TC-E 5008
  • HY-121736

    AGI-026

    Isocitrate Dehydrogenase (IDH) Neurological Disease
    AGI-12026 is brain-penetrant dual inhibitor of mutant IDH1 and 2. AGI-12026 shows partial inhibition of the IDH1-R132H homodimer as allosteric modulators. AGI-12026 has the potential for research of glioma [1].
    AGI-12026
  • HY-104036

    Isocitrate Dehydrogenase (IDH) Cancer
    IDH-305 is an orally available, mutant-selective and brain-penetrant IDH1 inhibitor that targets IDH1 (R132) mutation. IDH-305 exhibits greater than 200 fold selectivity for mutant IDH1 isoforms vs. WT (IC50= 27 nM (IDH1 R132H), 28 nM (IDH1 R132C), 6.14 µM (IDH1 WT)) [1] [2].
    <em>IDH</em>-305
  • HY-112289

    Isocitrate Dehydrogenase (IDH) Cancer
    IDH889 is an orally available, brain penetrant, allosteric and mutant specific inhibitor of isocitrate dehydrogenase 1 (IDH1). IDH889 has potent selectivity for IDH1 R132* mutations, with IC50s of 0.02 μM, 0.072 μM and 1.38 μM for IDH1 R132H, IDH1 R132C and IDH1 wt, respectively. IDH889 shows potent cellular inhibition of R-2-hydroxyglutarate (2-HG) production with an IC50 of 0.014 μM [1].
    <em>IDH</em>889
  • HY-112289B

    Isocitrate Dehydrogenase (IDH) Cancer
    (1R)-IDH889 is the isomer of IDH889 (HY-112289), and can be used as an experimental control. IDH889 is an orally available, brain penetrant, allosteric and mutant specific inhibitor of isocitrate dehydrogenase 1 (IDH1). IDH889 has potent selectivity for IDH1 R132* mutations, with IC50s of 0.02 μM, 0.072 μM and 1.38 μM for IDH1 R132H, IDH1 R132C and IDH1 wt, respectively. IDH889 shows potent cellular inhibition of R-2-hydroxyglutarate (2-HG) production with an IC50 of 0.014 μM [1].
    (<em>1</em>R)-<em>IDH</em>889
  • HY-N0328
    alpha-Mangostin
    3 Publications Verification

    α-Mangostin

    Reactive Oxygen Species Apoptosis Bacterial Fungal Virus Protease Cancer
    alpha-Mangostin (α-Mangostin) is a dietary xanthone with broad biological activities, such as antioxidant, anti-allergic, antiviral, antibacterial, anti-inflammatory and anticancer effects. It is an inhibitor of mutant IDH1 (IDH1-R132H) with a Ki of 2.85 μM.
    alpha-Mangostin
  • HY-114226
    Olutasidenib
    1 Publications Verification

    FT-2102

    Isocitrate Dehydrogenase (IDH) Inflammation/Immunology Cancer
    Olutasidenib (FT-2102) is a highly potent, orally active, brain penetrant and selective inhibitor of mutant Isocitrate dehydrogenase 1 (IDH1), with IC50 values of 21.2 nM and 114 nM for IDH1- R132H and IDH1- R132C, respectively . Olutasidenib (FT-2102) is under the study in the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) [1] [2].
    Olutasidenib
  • HY-19540
    GSK864
    4 Publications Verification

    Isocitrate Dehydrogenase (IDH) Cancer
    GSK864 is an isocitrate dehydrogenase 1 (IDH1) mutant inhibitor; inhibits IDH1 mutants R132C, R132H, and R132G with IC50 values of 8.8, 15.2 and 16.6 nM.
    GSK864
  • HY-18948
    GSK321
    1 Publications Verification

    GSK321 is a potent inhibitor of mutant isocitrate dehydrogenase 1 (IDH1) enzymes. GSK321 has high inhibitory and selectivity for mutant IDH1 enzymes. GSK321 can be used for the research of acute myeloid leukemia [1] [2].
    GSK321
  • HY-104042
    Vorasidenib
    3 Publications Verification

    AG-881

    Isocitrate Dehydrogenase (IDH) Cancer
    Vorasidenib (AG-881) is an orally available, brain penetrant second-generation dual mutant isocitrate dehydrogenases 1 and 2 (mIDH1/2) inhibitor. Vorasidenib (AG-881) exhibits nanomolar inhibition of (D)-2-hydroxyglutarate (D-2-HG), and the IC50 ranges of 0.04~22 nM against IDH1 R132C, IDH1 R132G, IDH1 R132H and IDH1 R132S and 7~14 nM against IDH2 R140Q and 130 nM against IDH2 R172K [1] [2].
    Vorasidenib
  • HY-143234

    Isocitrate Dehydrogenase (IDH) Cancer
    mIDH1-IN-1 (compound 43) is a potent and selective mIDH1 (mutant isocitrate dehydrogenases 1) inhibitor, with an IC50 of 961.5 nM. mIDH1-IN-1 potently inhibits intracellular 2-HG (2-hydroxyglutarate) production in HT1080 cells, with an EC50 of 208.6 ± 8.0 nM. mIDH1-IN-1 shows a significant anti-proliferation activity on IDH1 mutant-U-87 cells, with an IC50 of 41.8 nM. mIDH1-IN-1 is an antitumor agent, and can be used for IDH1 mutated solid tumors research [1].
    mIDH<em>1</em>-IN-<em>1</em>
  • HY-100020
    BAY-1436032
    3 Publications Verification

    Isocitrate Dehydrogenase (IDH) Cancer
    BAY-1436032 is a novel pan-mutant isocitrate dehydrogenase 1 (IDH1) inhibitor.
    BAY-1436032
  • HY-128888

    Isocitrate Dehydrogenase (IDH) Cancer
    (R,R)-GSK321 is a wild-type isocitrate dehydrogenase 1 (WT IDH1) inhibitor with an IC50 value of 120 nM. (R,R)-GSK321 as a mutant R132H IDH1 inhibitor, is an isomer of GSK321 with some wild-type cross reactivity [1].
    (R,R)-GSK321
  • HY-N0328R

    α-Mangostin (Standard)

    Fungal Reactive Oxygen Species Bacterial Apoptosis Virus Protease Cancer
    alpha-Mangostin (Standard) is the analytical standard of alpha-Mangostin. This product is intended for research and analytical applications. alpha-Mangostin (α-Mangostin) is a dietary xanthone with broad biological activities, such as antioxidant, anti-allergic, antiviral, antibacterial, anti-inflammatory and anticancer effects. It is an inhibitor of mutant IDH1 (IDH1-R132H) with a Ki of 2.85 μM.
    alpha-Mangostin (Standard)
  • HY-18082
    AGI-5198
    10+ Cited Publications

    IDH-C35

    Isocitrate Dehydrogenase (IDH) Cancer
    AGI-5198 (IDH-C35) is a potent and selective mutant IDH1 R132H inhibitor with an IC50 of 0.07 μM.
    AGI-5198
  • HY-136686

    Isocitrate Dehydrogenase (IDH) Cancer
    IDH-C227 is a potent and selective IDH1 R132H inhibitor. IDH-C227 has anticancer effcts [1].
    <em>IDH</em>-C227
  • HY-129545
    DS-1001b
    1 Publications Verification

    Isocitrate Dehydrogenase (IDH) Cancer
    DS-1001b is an orally active, blood-brain permeable, potent IDH-1 (isocitrate dehydrogenase-1) mutant inhibitor. DS-1001b has antitumor activity [1] [2] .
    DS-1001b
  • HY-N12390

    Isocitrate Dehydrogenase (IDH) Cancer
    Alternaphenol B2 is a selective IDH1 inhibitor from the coral-derived fungus Parengyodontium album SCSIO SX7W11. Alternaphenol B2 shows inhibitory activity against isocitrate dehydrogenase mutant R132H (IDH1m), with IC50 values of 41.9 μM [1].
    Alternaphenol B<em>2</em>
  • HY-RS13999

    Small Interfering RNA (siRNA) Others

    SUB1 Human Pre-designed siRNA Set A contains three designed siRNAs for SUB1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    SUB1 Human Pre-designed siRNA Set A
    SUB1 Human Pre-designed siRNA Set A
  • HY-146227

    Topoisomerase Apoptosis Cancer
    DNA topoisomerase II inhibitor 1 (compound 8ed) is a potent DNA topoisomerase II inhibitor. DNA topoisomerase II inhibitor 1 shows anti-proliferative activity. DNA topoisomerase II inhibitor 1 induces apoptosis and cell cycle arrest at sub G1 phase [1].
    DNA topoisomerase II inhibitor <em>1</em>
  • HY-128888B

    Isocitrate Dehydrogenase (IDH) Cancer
    (S,R)-GSK321 is a potent, selective mutant IDH1 inhibitor with IC50 values of 2.9, 3.8, 4.6 and 46 nM for R132G, R132C, R132H and WT IDH1, respectively, and >100-fold selectivity over IDH2. (S,R)-GSK321 induces decrease in intracellular 2-HG, abrogation of the myeloid differentiation block and induction of granulocytic differentiation at the level of leukemic blasts and more immature stem-like cells. (S,R)-GSK321can be used for research of acute myeloid leukemia (AML) and other cancers [1].
    (S,R)-GSK321
  • HY-R00008

    MicroRNA Cancer
    hsa-let-7d-3p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.
    hsa-let-7d-3p mimic
    hsa-let-7d-3p mimic
  • HY-RI00008

    MicroRNA
    hsa-let-7d-3p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
    hsa-let-7d-3p inhibitor
    hsa-let-7d-3p inhibitor
  • HY-112499S

    Vitamin K2-7-d<sub>7sub>; Vitamin K2(35)-d<sub>7sub>; Vitamin MK-7-d<sub>7sub>

    Isotope-Labeled Compounds Cardiovascular Disease
    Menaquinone-7-d7 is the deuterium labeled Menaquinone-7. Menaquinone-7 (Vitamin K2-7), belongs to a class of K2-vitamin homologs, is originally discovered as the anti-hemorrhagic factors[1]. Menaquinone-7 (Vitamin K2-7) is identified as the most bioactive cofactor for the carboxylation reaction of Gla-proteins [2]. Supplementation with Menaquinone-7 (Vitamin K2-7) is a pharmacological option for activating matrix Gla protein and intervening in the progression of calcific aortic valve stenosis (CAVS)[3].
    Menaquinone-<em>7-d</em><em>7</em>
  • HY-B0511S2

    Vitamin B7-d<sub>2sub>; Vitamin H-d<sub>2sub>; D-Biotin-d<sub>2sub>

    Endogenous Metabolite Metabolic Disease
    Biotin-d2 is the deuterium labeled Biotin. Biotin is an enzyme co-factor present in minute amounts in every living cell.
    Biotin-d<em>2</em>
  • HY-R00008A

    MicroRNA
    hsa-let-7d-3p agomirs are chemically-modified double-strand miRNA mimics with modified mature miRNA strand: 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 3' end cholesterol group, and full-length nucleotide 2'-methoxy modification. They are designed to mimic endogenous miRNAs and recommended for miRNA functional studies. Compared with miRNA mimics, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.
    hsa-let-7d-3p agomir
    hsa-let-7d-3p agomir
  • HY-B0511S

    Vitamin B7 d<sub>2sub>-1; Vitamin H d<sub>2sub>-1; D-Biotin d<sub>2sub>-1

    Endogenous Metabolite Metabolic Disease
    Biotin-d2-1 is the deuterium labeled Biotin. Biotin is an enzyme co-factor present in minute amounts in every living cell.
    Biotin-d<em>2</em>-<em>1</em>
  • HY-RI00008A

    MicroRNA
    hsa-let-7d-3p antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.
    hsa-let-7d-3p antagomir
    hsa-let-7d-3p antagomir
  • HY-B0389S26

    Glucose-d<sub>2sub>-2; D-(+)-Glucose-d<sub>2sub>-2; Dextrose-d<sub>2sub>-2

    Endogenous Metabolite Metabolic Disease Cancer
    D-Glucose-d2-2 is the deuterium labeled D-Glucose. D-Glucose (Glucose), a monosaccharide, is an important carbohydrate in biology. D-Glucose is a carbohydrate sweetener and critical components of the general metabolism, and serve as critical signaling mol
    D-Glucose-d<em>2</em>-<em>2</em>
  • HY-122814

    Hedgehog Others Neurological Disease Cancer
    Hedgehog IN-1 (Compound 7d) is an inhibitor for Hedgehog protein with IC50 of 70 nM [1].
    Hedgehog IN-<em>1</em>
  • HY-100753
    STAT3-IN-1
    5+ Cited Publications

    STAT3-IN-1 (compound 7d) is an excellent, selective and orally active STAT3 inhibitor, with IC50 values of 1.82 μM and 2.14 μM in HT29 and MDA-MB 231 cells, respectively. STAT3-IN-1 (compound 7d) induces tumor cells apoptosis [1].
    STAT3-IN-<em>1</em>
  • HY-Y0418S4

    Dulcitol-d<sub>2sub>; Melampyrit-d<sub>2sub>; NSC 1944-d<sub>2sub>

    Isotope-Labeled Compounds Endogenous Metabolite Others
    Dulcite-d2 is the deuterium labeled Dulcite. Dulcite is a sugar alcohol with a slightly sweet taste which is a metabolic breakdown product of galact[1][2].
    Dulcite-d<em>2</em>
  • HY-B0400S9

    Sorbitol-d<sub>2sub>-2; D-Glucitol-d<sub>2sub>-2

    Endogenous Metabolite Others
    D-Sorbitol-d2-2 is the deuterium labeled D-Sorbitol. D-Sorbitol (Sorbitol) is a six-carbon sugar alcohol and can used as a sugar substitute. D-Sorbitol can be used as a stabilizing excipient and/or isotonicity agent, sweetener, humectant, thickener and di
    D-Sorbitol-d<em>2</em>-<em>2</em>

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: